Literature DB >> 21290232

α(1)-Adrenoceptors in the urinary tract.

Shizuo Yamada1, Yoshihiko Ito.   

Abstract

α(1)-Adrenoceptors have been identified and characterized extensively by functional, radioligand-binding, and molecular biological techniques. Molecular clones have been isolated for three α(1)-subtypes (α(1a), α(1b), and α(1d)), and these subtypes are also functionally characterized. α(1)-Adrenoceptors are present in the prostate, urethra, bladder (urothelium, smooth muscle, and afferent nerves), ureter, vas deferens, peripheral ganglia, nerve terminals, vascular tissues, and central nervous system (CNS), and they could all potentially influence overall urinary function and contribute to both the therapeutic and adverse effects of α(1)-adrenoceptor antagonists in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). This review aimed to discuss the relevant physiological and pharmacological roles and molecular biology of α(1)-adrenoceptor subtypes in the prostate, urethra, bladder, ureter, and CNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21290232     DOI: 10.1007/978-3-642-16499-6_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  7 in total

Review 1.  The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.

Authors:  Karl-Erik Andersson; Donna B Boedtkjer; Axel Forman
Journal:  Ther Adv Urol       Date:  2016-11-04

Review 2.  [Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention].

Authors:  S Mühlstädt; M Oelke
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

3.  Urine Flow Dynamics Through Prostatic Urethra With Tubular Organ Modeling Using Endoscopic Imagery.

Authors:  Takuro Ishii; Yoichi Kambara; Tomonori Yamanishi; Yukio Naya; Tatsuo Igarashi
Journal:  IEEE J Transl Eng Health Med       Date:  2014-08-04       Impact factor: 3.316

Review 4.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

5.  The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction.

Authors:  Martin Hennenberg; Frank Strittmatter; Henning Schmetkamp; Beata Rutz; Sebastian Walther; Christian G Stief; Christian Gratzke
Journal:  J Biomed Sci       Date:  2013-07-02       Impact factor: 8.410

6.  Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Authors:  Ling-ling Zhu; Zhi-jun Feng; Quan Zhou
Journal:  Clin Interv Aging       Date:  2015-03-26       Impact factor: 4.458

7.  Pharmacology of the lower urinary tract.

Authors:  Martin Hennenberg; Christian G Stief; Christian Gratzke
Journal:  Indian J Urol       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.